San Francisco, CA, United States of America

Peter Flynn

USPTO Granted Patents = 10 (Patent Applications = 1)

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 3.6

ph-index = 3

Forward Citations = 75(Granted Patents)

Company Filing History:

Kalobios Pharmaceuticals, Inc.

patents

4. 1 out of 1

Taligen Therapeutics, Inc.

patent

5. 1 out of 196

Alexion Pharmaceuticals, Inc.

patents

Years Active: 2011-2024

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12152085 - Compositions and methods to regulate Renalase in the treatment of cancer (2024-11-26),

2. 11370846 - Compositions and methods to regulate Renalase in the treatment of cancer (2022-06-28),

3. 10618975 - Antibody to Renalase (2020-04-14),

4. 10273311 - Compositions to regulate renalase in the treatment of diseases and disorders (2019-04-30),

5. 9096677 - Humaneered anti-factor B antibody (2015-08-04),

6. 8878876 - Systems and methods for managing the positioning and sizing of objects in electronic content (2014-11-04),

7. 8650484 - Systems and methods for creating computer content using multiple editing contexts (2014-02-11),

8. 8453112 - Systems and methods for collaboratively creating applications using a multiple source file project that can be accessed and edited like a single file (2013-05-28),

9. 7981843 - Antibody specificity transfer using minimal essential binding determinants (2011-07-19),

10. 7964705 - Humaneered anti-factor B antibody (2011-06-21),

Title: **Innovative Contributions of Inventor Peter Flynn**

Introduction

Peter Flynn is a prominent inventor based in San Francisco, California, with an impressive portfolio comprising 10 patents. His work primarily focuses on advancements in medical treatments, particularly concerning the regulation of renalase in the context of cancer therapy. His innovations exemplify the intersection of research and practical application, offering promising therapeutic options.

Latest Patents

Among his latest contributions, Flynn has developed compositions and methods aimed at regulating renalase to treat cancer. His invention provides significant details about binding and inhibiting renalase activity. In one particular embodiment, the renalase binding molecule demonstrated an ability to inhibit renalase activity, which can be advantageous in diseases where reducing renalase activity is beneficial. These novel therapeutics could pave the way for new cancer treatment strategies, showcasing Flynn's commitment to addressing critical healthcare challenges.

Career Highlights

Throughout his career, Peter Flynn has worked at notable institutions, contributing to the innovation landscape. He has spent time at Yale University, where he likely engaged in groundbreaking research, and at Adobe Systems Incorporated, where his expertise in technology and innovation may have influenced advancements in their products and services.

Collaborations

In his professional journey, Flynn has collaborated with distinguished colleagues, including Gary Desir and Abigail Hunt. These interactions with fellow innovators and researchers have helped foster a collaborative environment that encourages the exchange of ideas and the pursuit of groundbreaking inventions.

Conclusion

Peter Flynn's innovative spirit and dedication to research are evident in his substantial contributions to medical science and the technology sector. With a solid foundation of patents and fruitful collaborations, his work continues to inspire future inventions and therapeutic developments in the fight against diseases like cancer.

This text is generated by artificial intelligence and may not be accurate.